A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma

Oncology (Switzerland)

Volumn 82, Issue 6, 2012, Pages 333-340

  Stenner, Frank ^a   Chastonay, Rahel ^a   Liewen, Heike ^a   Haile, Sarah R ^b   Cathomas, Richard ^e   Rothermundt, Christian ^d   Siciliano, Raffaele D ^c   Stoll, Susanna ^f   Knuth, Alexander ^a   Buchler, Tomas ^g   Porta, Camillo ^h   Renner, Christoph ^a   Samaras, Panagiotis ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c TRIEMLI HOSPITAL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

^g FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Renal cell carcinoma; Sorafenib; Sunitinib; Treatment regimens; Tyrosine kinase inhibitors

Indexed keywords

SORAFENIB; SUNITINIB;

ARTICLE; CANCER SURVIVAL; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861880926     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338001     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. (Pubitemid 46089673)
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garciadel- Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
4. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
5. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa- 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
6. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
7. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
8. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86, discussion 86. (Pubitemid 350216728)
9. Richter S, Pfister D, Thüer D, Engelmann UH, Heidenreich A: Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib (abstractV684). Onkologie 2008; 31: 234.
10. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U: Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-354.
11. Shepard DR, Rini BI, Garcia JA, Hutson TE, Elson P, Gilligan T, Nemec C, Lopez R, Borner D, Dreicer R, Bukowski RM: A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab (abstract). J Clin Oncol 2008; 26(suppl):5123.
12. Choueiri TK, Brick AJ, Mcdermott D, Clement J, Kwabi C, Shah K, Chen K, Duh MS, Neary MP, Oh WK: Treatment and dosingpatterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC) (abstract). Ann Oncol 2008; 19: 593.
13. Heuer R, Eichelberg C, Zacharias M, Heinzer H: Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib. J Urol 2009; 181(suppl 1):501.
14. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67.
15. Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdona S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S: Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 4469-4474.
16. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182: 29-34, discussion 34.
17. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010; 116: 5383-5390.
18. Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol 2012; 23: 395-401.
19. Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Puhse G, Steiner T: Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011; 29: 361-366.
20. Porta C, Procopio G, Carteni G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E: Sequential use of sorafenib and sunitinib in advanced renalcell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011; 108(8 Pt 2):E250-E257.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
22. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2009 (http://www.R-project.Org).
23. Rufibach K: Reporttools: R functions to generate latex tables of descriptive statistics. J Stat Soft 2009; 31: 1-7.
24. Ambring A, Stierner, U, Anders O, Björholt I: Sorafenib and sunitinib in renal cell cancer: a study based on register data (abstract). J Clin Oncol 2011; 29: 4600.
25. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 1931-1939.
26. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY: Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 2010; 76: 430-434.
27. Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grunwald V, Weikert S: Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011; 60: 1163-1170.
28. Grunwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S: Treatment of everolimusresistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 2011; 105: 1635-1639.
29. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA: Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012; 48: 333-339.
30. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P: Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev 2010; 36: 16-23.
31. Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α 2a (IFN) in metastatic renal cell carcinoma (mRCC) (abstract). J Clin Oncol 2009; 27(suppl):5020.
32. Porta C, Procopio G, Carteni G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Lo Re G, Ricotta R, Zustovich F: An Italian multicentre retrospective analysis of 189 advanced renal-cell carcinoma patients treated sequentially, either with sorafenib followed by sunitinib, or vice versa (abstract 922P). Ann Oncol 2010; 21:viii289.